SRR8518222
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.620
- ALLOGRAFT_REJECTION+0.450
- E2F_TARGETS+0.450
- G2M_CHECKPOINT+0.350
- IL6_JAK_STAT3_SIGNALING+0.330
- MYC_TARGETS_V2+0.290
- MYC_TARGETS_V1+0.260
- INFLAMMATORY_RESPONSE+0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.650
- NOTCH_SIGNALING-0.500
- UV_RESPONSE_DN-0.500
- TGF_BETA_SIGNALING-0.470
- ANGIOGENESIS-0.450
- CHOLESTEROL_HOMEOSTASIS-0.420
- ESTROGEN_RESPONSE_EARLY-0.410
- MYOGENESIS-0.400
- APICAL_JUNCTION-0.390
- ESTROGEN_RESPONSE_LATE-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_1542_T2_RNA | — | D | 0.915 |
| 2 | TCGA-CR-6487-01A-11R-1873-07 | — | — | 0.904 |
| 3 | SRR25617828 | — | D | 0.900 |
| 4 | BSR_11_0107_E3_S77 | — | D | 0.899 |
| 5 | SRR8518297 | — | E | 0.898 |
| 6 | SRR8613746 | — | D | 0.886 |
| 7 | bd9c63e1-a1cb-4b2f-a909-839ce2fd8618 | — | — | 0.883 |
| 8 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.876 |
| 9 | SRR8613734 | — | D | 0.866 |
| 10 | SRR1313144 | — | D | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.620 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |